Icahn Sues Amylin For Docs On Rebuffed $3.5B Bristol Bid
Activist investor Carl Icahn stepped up his pressure Thursday on Amylin Pharmaceuticals Inc. over the company's alleged rejection of a $3.5 billion offer from Bristol-Myers Squibb Co., filing suit to force...To view the full article, register now.
Already a subscriber? Click here to view full article